Sapience Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Team
    • Directors
    • Advisors
  • Our Approach
    • Overview
    • Therapeutic Approach
    • Discovery Platform
  • Pipeline
    • Overview
    • ST101
    • β-Catenin Antagonist
    • cJun Antagonist
    • cMyc Antagonist
    • FoxP3 Antagonist
  • Partnering
  • Careers
  • News & Media
    • Press Releases
    • Publications
    • Presentations
    • Email Alerts
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Publications
  • Presentations
  • Email Alerts
Sep 10, 2019 8:30am EDT

Sapience Therapeutics to Present at the 2019 BIO Investor Forum

Sep 04, 2019 8:30am EDT

Sapience Therapeutics Builds Clinical Team with Appointment of Alice Bexon, MD, as Chief Medical Officer

May 16, 2019 8:30am EDT

Sapience Therapeutics to Present at the 2019 BIO International Convention

Mar 14, 2019 8:30am EDT

Sapience Therapeutics to Present Poster on ST101 at the 2019 American Association for Cancer Research Annual Meeting

Jan 31, 2019 8:30am EST

Sapience Therapeutics to Present at 2019 BIO CEO & Investor Conference

Dec 11, 2018 8:30am EST

Sapience Therapeutics to Present at Biotech Showcase 2019

Jun 26, 2018 8:59am EDT

Sapience Therapeutics, Inc. Selected as a Winner of the JLABS NYC QuickFire Challenge

Apr 05, 2018 9:11am EDT

Sapience Therapeutics Enters into Drug Discovery Pact with the University of Bath

May 10, 2017 9:36am EDT

Sapience Therapeutics Adds Biotech Veteran, Christian S. Schade, to Board of Directors

Mar 29, 2017 9:36am EDT

Sapience Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ST-36 for the Treatment of Glioma

  • Previous
  • 1
  • 2
  • 3
  • Next
RSS
© 2021 Sapience Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap